Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

Antibody-Drug+Conjugates

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (735) Antibody-Drug Conjugates (ADCs) (102) ADC Antibody (56) ADC Payload (91) Akt (1) ALCAM/CD166 (1) Amino Acid Derivatives (5) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (3) Antifolate (1) Apoptosis (32) Bacterial (7) Biochemical Assay Reagents (6) Btk (2) c-Kit (1) c-Met/HGFR (5) Carbonic Anhydrase (1) Caspase (2) CCR (7) CD19 (2) CD2 (1) CD22 (5) CD276/B7-H3 (4) CD3 (3) Claudin (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (12) DNA/RNA Synthesis (6) Drug Derivative (4) Drug Intermediate (24) Drug Metabolite (1) Drug-Linker Conjugates for ADC (85) E3 Ligase Ligand-Linker Conjugates (1) EGFR (27) Endothelin Receptor (1) Environmental Pollutants (1) Epigenetic Reader Domain (1) ERK (1) Eukaryotic Initiation Factor (eIF) (2) Ferroptosis (1) FGFR (2) Folate Receptor (FR) (3) GLP Receptor (1) Glucocorticoid Receptor (6) Glutathione Peroxidase (1) Guanylate Cyclase (1) IGF-1R (1) Integrin (1) Isotope-Labeled Compounds (11) Kinesin (3) MDM-2/p53 (1) Mesothelin (2) Microtubule/Tubulin (63) Mitochondrial Metabolism (1) Mitosis (1) mTOR (1) Mucin (2) NAMPT (2) Nectin-4 (3) Notch (3) Nucleoside Antimetabolite/Analog (1) PD-1/PD-L1 (5) Phosphodiesterase (PDE) (1) PI3K (3) PROTAC Linkers (208) PROTAC-Linker Conjugates for PAC (1) PROTACs (1) Ras (1) Reference Standards (9) ROR (1) Sodium Channel (4) Sodium Phosphate Cotransporter (1) Src (1) STING (6) TAM Receptor (3) Target Protein Ligand-Linker Conjugates (1) TGF-β Receptor (1) TNF Receptor (4) Toll-like Receptor (TLR) (4) Topoisomerase (40) Transmembrane Glycoprotein (9) TROP2 (7) VEGFR (1)
By Research Areas:	Cancer (1093) Cardiovascular Disease (1) Infection (12) Inflammation/Immunology (45) Metabolic Disease (2) Neurological Disease (1)
Click Chemistry:	ADC Synthesis (229) TCO (15) DBCO (57) PROTAC Synthesis (52) BCN (21) Azide (84) Tetrazine (32) Alkynes (46)

1142

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

249

Click Chemistry

GMP Molecules

Targets Recommended: Antibody-Drug Conjugates (ADCs) ADC Linker

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-133540

Maleimide-DOTA 2 Publications Verification Maleimido-mono-amide-DOTA	ADC Linker	Inflammation/Immunology Cancer
Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-W002213

N-Hydroxysulfosuccinimide sodium 2 Publications Verification	ADC Linker	Cancer
N-Hydroxysulfosuccinimide (sodium) is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-42146

BMPS	ADC Linker	Cancer
BMPS is a nonclaevable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-44246

MC-Gly-Gly-Phe-Gly 2 Publications Verification Mc-GGFG-OH	ADC Linker	Cancer
MC-Gly-Gly-Phe-Gly is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

HY-132162

7-MAD-MDCPT	ADC Payload	Cancer
7-MAD-MDCPT, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .

HY-44222

MAC glucuronide linker-2	ADC Linker	Cancer
MAC glucuronide linker-2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-44235

MC-Gly-Gly-Phe	ADC Linker	Cancer
MC-Gly-Gly-Phe is a cleavable linker used for antibody-drug conjugates (ADC).

HY-126364

Mc-Val-Ala-PAB	ADC Linker	Cancer
Mc- Val- Ala- PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-140014

Val-Cit	ADC Linker	Cancer
Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-W023121

Fmoc-Gly-Gly-OH	ADC Linker	Cancer
Fmoc-Gly-Gly-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-79129

Fmoc-D-Trp(Boc)-OH	ADC Linker	Cancer
Fmoc-D-Trp(Boc)-OH is a cleavable ADC linker that used in the synthesis of antibody-drug conjugates (ADCs).

HY-126353

Fmoc-Val-Ala-PAB-OH	ADC Linker	Cancer
Fmoc-Val-Ala-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-101151

sulfo-SPDB	ADC Linker	Cancer
sulfo-SPDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-101153

MC-Val-Ala-OH 1 Publications Verification	ADC Linker	Cancer
MC-Val-Ala-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-126498

PDEC-NB	ADC Linker	Cancer
PDEC-NB is a disulfide cleavable linker used for the antibody-drug conjugate (ADC).

HY-12448

SPDB	ADC Linker	Cancer
SPDB is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs) .

HY-41919

Mal-L-PA-NH-Boc mDPR(boc); (S)-MALEOYL-DPR(BOC)-OH·DCHA	ADC Linker	Cancer
Mal-L-PA-NH-Boc is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-W011541

SIA Crosslinker Iodoacetic acid N-hydroxysuccinimide ester; N-Succinimidyl Iodoacetate	ADC Linker	Cancer
SIA Crosslinker is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-141141

Boc-Val-Cit-PAB	ADC Linker	Cancer
Boc-Val-Cit-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-135418

Fmoc-Asp-NH2	ADC Linker	Cancer
Fmoc-Asp-NH2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-W038702

Boc-Val-Cit-OH	ADC Linker	Cancer
Boc-Val-Cit-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-130932

Boc-Val-Ala-PAB-PNP	ADC Linker	Cancer
Boc-Val-Ala-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-140098

Boc-Cystamine	ADC Linker	Cancer
Boc-Cystamine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-140129

NHS-SS-biotin	ADC Linker	Cancer
NHS-SS-biotin is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-128929

Fmoc-PEA	ADC Linker	Cancer
Fmoc-PEA (Example 1-2) is a used as a cleavable linker for antibody-drug conjugates (ADC) .

HY-140140

PC Mal-NHS carbonate ester	ADC Linker	Cancer
PC Mal-NHS carbonate ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-150043A

MDTF	ADC Linker	Cancer
MDTF is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-126495A

Sulfo-LC-SPDP sodium	ADC Linker	Cancer
Sulfo-LC-SPDP sodium is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-159794

Azido-methyltetrazine di-arm linker	ADC Linker	Cancer
Azido-methyltetrazine di-arm linker is a multivalent ADC linker for the synthesis of antibody-drug conjugates (ADCs) .

HY-129362

Phe-Lys(Fmoc)-PAB	ADC Linker	Cancer
Phe-Lys(Fmoc)-PAB is a cathepsin cleavable ADC linker used for the antibody-drug conjugates (ADCs) .

HY-130961

Boc-Val-Dil-Dap-OH	ADC Linker	Cancer
Boc-Val-Dil-Dap-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-P99719

Lupartumab Amadotin BAY 1129980; Anti-C4.4a Antibody-drug conjugates	Antibody-Drug Conjugates (ADCs)	Cancer
Lupartumab Amadotin (BAY 1129980) is an antibody–drug conjugate (ADC) consisting of a fully human C4.4A (LYPD3)-targeting mAb (BAY 1135626) (HY-147281) conjugated to a novel, highly potent derivative of the microtubule-disrupting cytotoxic drug auristatin via a noncleavable alkyl hydrazide linker. Lupartumab Amadotin can be used for the research of non-small cell lung cancer .

HY-160182

INX-P	ADC Linker Glucocorticoid Receptor	Inflammation/Immunology
INX-P is glucocorticosteroid-target antibody drug conjugate (ADC) .

HY-129368

SPDMV 1 Publications Verification	ADC Linker	Cancer
SPDMV is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs) .

HY-126405

SMPT	ADC Linker	Cancer
SMPT is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-132162A

7-MAD-MDCPT hydrochloride	ADC Payload	Cancer
7-MAD-MDCPT hydrochloride, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .

HY-140096

Aminoethyl-SS-propionic acid	ADC Linker	Cancer
Aminoethyl-SS-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-P11295

Fmoc-GGFG-PAB-PNP	ADC Linker	Cancer
Fmoc-GGFG-PAB-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADC) .

HY-126530

PPC-NB	ADC Linker	Cardiovascular Disease Cancer
PPC-NB is a glutathione cleavable linker used for the antibody-drug conjugate (ADC) .

HY-160157

IM-2	Drug-Linker Conjugates for ADC	Cancer
IM-2 is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-129360

Ala-Ala-Asn-PAB	ADC Linker	Cancer
Ala-Ala-Asn-PAB is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .

HY-150043

MDTF free acid	ADC Linker	Cancer
MDTF free acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-23641

NH-bis(C1-Boc)	ADC Linker	Cancer
NH-bis(C1-Boc)is a uncleavable linker used for antibody-drug conjugates (ADC).

HY-129349

Phe-Lys(Trt)-PAB	ADC Linker	Cancer
Phe-Lys(Trt)-PAB is a cathepsin cleavable ADC linker used for the antibody-drug conjugates (ADCs) .

HY-129365

SNPB	ADC Linker	Cancer
SNPB is a cleavable linker that is used for making antibody-drug conjugate (ADC).

HY-129376

Sulfo-SNPB	ADC Linker	Cancer
Sulfo-SNPB is a cleavable linker that is used for making antibody-drug conjugate (ADC).

HY-W071006

PPC-NHS ester 2,5-Dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)butanoate	ADC Linker	Cancer
PPC-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133542

Dimethylamine-SPDB	ADC Linker	Cancer
Dimethylamine-SPDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-129370

SPDB-sulfo	ADC Linker	Cancer
SPDB-sulfo is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs) .

HY-126531

DMAC-PDB	ADC Linker	Cancer
DMAC-PDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library

115 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 115 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Type

HY-138298

Trastuzumab deruxtecan (solution)

5 Publications Verification

T-DXd (solution); DS-8201 (solution); DS-8201a (solution)

Fluorescent Dyes

Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-138298A

Trastuzumab deruxtecan

5 Publications Verification

T-DXd; DS-8201; DS-8201a

Fluorescent Dyes

Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-141598

Datopotamab deruxtecan (solution)

2 Publications Verification

DS-1062 (solution); Dato-DXd (solution)

Fluorescent Dyes

Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 K_d of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .

HY-132254

Sacituzumab govitecan Maximum Cited Publications 10 Publications Verification IMMU-132	Fluorescent Dyes
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .

HY-132254A

Sacituzumab govitecan (solution) Maximum Cited Publications 10 Publications Verification IMMU-132 (solution)	Fluorescent Dyes
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .

HY-164789

Sacituzumab tirumotecan

SKB264; MK-2870

Fluorescent Dyes

Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC₅₀ of 2.787 ng/ml, TROP2 K_a of 0.3083 nM, and topoisomerase I IC₅₀ of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer .

HY-P99016B

Enfortumab vedotin-ejfv (solution)

1 Publications Verification

Fluorescent Dyes

Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-P9921A

Trastuzumab emtansine (solution)

5+ Cited Publications

Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)

Fluorescent Dyes

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .

HY-P99016A

Enfortumab vedotin-ejfv

1 Publications Verification

Fluorescent Dyes

Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-P3371

Ifinatamab deruxtecan

DS-7300a; MABX-9001a; I-DXd

Fluorescent Dyes

Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-141601

Telisotuzumab vedotin

2 Publications Verification

ABBV-399

Fluorescent Dyes

Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research .

HY-132253

Polatuzumab vedotin

1 Publications Verification

Fluorescent Dyes

Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-171945

Telisotuzumab Adizutecan

ABBV-400; Temab-A

Fluorescent Dyes

Telisotuzumab Adizutecan (ABBV-400) is an anti-c-Met antibody-drug conjugate (ADC). Telisotuzumab Adizutecan is composed of the humanized anti-c-Met antibody Telisotuzumab (HY-P99391) and the topoisomerase 1 inhibitor (7-MAD-MDCPT) (HY-132162). Telisotuzumab Adizutecan exhibits significant anti-tumor activity against advanced solid tumors such as colorectal cancer, gastric cancer, and non-small cell lung cancer .

HY-164992

Trastuzumab vedotin

2 Publications Verification

MRG002; Trastuzumab MMAE

Fluorescent Dyes

Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a K_d of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .

HY-171135

Cetuximab MMAE	Fluorescent Dyes
Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity .

HY-171265

Becotatug vedotin MRG003	Fluorescent Dyes
Becotatug vedotin (MRG003) is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575) .

HY-177434

Precemtabart tocentecan

Precem-TcT; M 9140

Fluorescent Dyes

Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .

HY-126851

Fluorescein-DBCO	Fluorescent Dyes
Fluorescein-DBCO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Fluorescein-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-123687

DBCO-Sulfo-NHS ester sodium	Fluorescent Dyes
DBCO-Sulfo-NHS ester sodium is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Sulfo-NHS ester (sodium) is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-171821

PF-08046054 SGN-PDL1V	Fluorescent Dyes
PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors

HY-170554

ABBV-706

Fluorescent Dyes

ABBV-706 is a SEZ6-targeted topoisomerase 1 inhibitor Antibody-Drug Conjugates (ADCs), which is composed of the Linker-Payload conjugation (HY-148820) and the Anti-SEZ6 Antibody (SC17) (HY-P991041). ABBV-706 can inhibit cancer cells proliferation and induce DNA damage and G2/M arrest. ABBV-706 exhibits high efficacy against small cell lung cancer (SCLC), neuroendocrine tumors (NENs) and central nervous system (CNS) tumors .

HY-177442

DS-3939a

DS-3939

Fluorescent Dyes

DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .

HY-164919

Calotatug ginistinag XMT-2056	Fluorescent Dyes
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate targeting HER2, with an effective payload connected via a linker (LP, HY-148067) to a STING agonist (STING agonist-20, HY-148068), and has potential immune activation and anticancer activity .

HY-173639

AZD0516

Fluorescent Dyes

AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting six-transmembrane epithelial antigen of the prostate-2 (STEAP2). The anti-STEAP2 monoclonal antibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker (HY-173635) bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631). AZD0516 can be used for the study of prostate cancer .

HY-164729

FZ-AD005

Fluorescent Dyes

FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The K_d value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .

HY-164894

ABBV-3373	Fluorescent Dyes
ABBV-3373 is an anti-TNF antibody-drug conjugate (ADC). ABBV-3373 consists of a humanized TNF antibody Adalimumab (HY-P9908) conjugated to a glucocorticoid receptor agonist (HY-148436). ABBV-3373 can be used for the research of rheumatoid arthritis .

HY-132253A

Polatuzumab vedotin (solution)

1 Publications Verification

Fluorescent Dyes

Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-158109

M3554	Fluorescent Dyes
M3554 is an anti-GD2 antibody-drug conjugate (ADC) based on the humanized anti-GD2 antibody. M3554 consists of the humanized monoclonal antibody hu14.18 (K322A) (HY-P991040) linked to a topoisomerase 1 inhibitor Exatecan (HY-13631) via a cleavable β-glucuronide linker. M3554 can be used for the study of neuroblastoma, osteosarcoma or glioma .

HY-164762

Trastuzumab rezetecan SHR-A1811	Fluorescent Dyes
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .

HY-D2910

Ox4	Fluorescent Dyes
Ox4 is a selective covalent modifier targeting Methionine residues. Ox4 is promising for research of protein functionalization, antibody-drug conjugate (ADC) synthesis, and proteome-wide identification of reactive methionine sites .

HY-156712

Depatuxizumab MMAE	Fluorescent Dyes
Depatuxizumab MMAE is an *antibody-drug conjugate* (ADC) comprising an anti EGFR monoclonal antibody (Depatuxizumab) (HY-P99849) and the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162). Depatuxizumab MMAE can be used for the study of EGFR-expressing advanced solid tumors.

HY-164893

ABBV-154	Fluorescent Dyes
ABBV-154 is an anti-TNF antibody-drug conjugate (ADC). ABBV-154 is composed of the humanized antibody Adalimumab (HY-P9908) conjugated with a glucocorticoid receptor modulator (HY-137883). ABBV-154 can be used in studies of rheumatoid arthritis, Crohn's disease and polymyalgia rheumatica .

HY-W000423G

DBCO-amine	Fluorescent Dyes
DBCO-amine (GMP) is a GMP grade DBCO-amine (HY-W000423). DBCO-amine is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups. DBCO-amine is used in the synthesis of antibody-drug conjugates (ADCs) .

HY-145622

Mecbotamab vedotin

BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC

Fluorescent Dyes

Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162) .

HY-15579G

MMAF

Monomethylauristatin F

Fluorescent Dyes

MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-171544

AGS-16C3F AGS-16M8F	Fluorescent Dyes
AGS-16C3F is an antibody-drug conjugate (ADC) targeting ENPP3. AGS-16C3F is composed of ENPP3-targeting Anti-ENPP3/CD203c Antibody (HY-P990315) linked to Monomethyl auristatin F (HY-15579) via a linker. AGS-16C3F has anti-tumor activity and can be used in the study of metastatic renal cell carcinoma (mRCC) .

HY-171747

AMT-562

Fluorescent Dyes

AMT-562 is an antibody-drug conjugate (ADC) consisting of a novel anti-HER3 antibody Ab562 (HY-P991505) conjugated to the linker MC-VA-PAB and the topoisomerase I inhibitor Exatecan (HY-13631). The ADC toxic molecule and linker portion are MC-VA-PAB-Exatecan (HY-147270). AMT-562 can induce apoptosis and has antitumor activity against pancreatic, esophageal, and gastric cancers .

HY-78921AG

Fmoc-3VVD-OH	Fluorescent Dyes
Fmoc-3VVD-OH (GMP) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78932G

Dap-NE hydrochloride	Fluorescent Dyes
Dap-NE hydrochloride (GMP) is Dap-NE hydrochloride (HY-78932A) produced by using GMP guidelines. Dap-NE hydrochloride is an intermediate used in the synthesis of antibody-drug conjugates (ADCs) .

HY-176559

LacNAc-VC-PAB-MMAE	Fluorescent Dyes
LacNAc-VC-PAB-MMAE is a component of an *Antibody-Drug Conjugate* (ADC). LacNAc-VC-PAB-MMAE is assembled onto the N-glycosylation site of Trastuzumab (HY-P9907) by WT Endo-S2 .

HY-15578G

McMMAF Maleimidocaproyl monomethylauristatin F	Fluorescent Dyes
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

HY-20336G

Mc-Val-Cit-PABC-PNP	Fluorescent Dyes
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-P9994

Pertuzumab zuvotolimod

SBT6050

Fluorescent Dyes

Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .

HY-P991668

PF-06688992 Antibody	Fluorescent Dyes
PF-06688992 Antibody is an antibody targeting GD3. PF-06688992 Antibody can be used for the synthesis of the antibody-drug conjugate PF-06688992 (HY-P991668) .

HY-131833G

Fmoc-Gly-Gly-Phe-OH	Fluorescent Dyes
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133540G

Maleimide-DOTA Maleimido-mono-amide-DOTA	Fluorescent Dyes
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-171191

REGN5093-M114	Fluorescent Dyes
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528) .

HY-172820

Trastuzumab envedotin

DP303c

Fluorescent Dyes

Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .

HY-131990G

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH	Fluorescent Dyes
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-131990). MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-177414

BB-1701

Fluorescent Dyes

BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 is composed of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), a microtubule inhibitor (Eribulin) (HY-13442), and the drug-linker conjugate for ADC is Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 has a potent cytotoxicity and bystander effects on tumors with heterogeneous target expression. BB-1701 significantly induces immunogenic cell death and the activation of the immune .

Cat. No.	Product Name	Type

HY-W010162

H-Ala-Ala-OH L-Alanyl-L-alanine; Ala-Ala	Biochemical Assay Reagents
H-Ala-Ala-OH is a substrate of human intestinal oligopeptide transporter (PEPT1/SLC15A1), with an IC₅₀ of 0.25 mM and an EC₅₀ of 0.08 mM against human PEPT1. When used as a dipeptide linker in antibody-drug conjugates (ADCs) loaded with glucocorticoid receptor regulator payloads, H-Ala-Ala-OH enables efficient intracellular payload release .

HY-W000423G

DBCO-amine	Biochemical Assay Reagents
DBCO-amine (GMP) is a GMP grade DBCO-amine (HY-W000423). DBCO-amine is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups. DBCO-amine is used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15579G

MMAF

Monomethylauristatin F

Biochemical Assay Reagents

HY-78921AG

Fmoc-3VVD-OH	Biochemical Assay Reagents
Fmoc-3VVD-OH (GMP) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78932G

Dap-NE hydrochloride	Biochemical Assay Reagents
Dap-NE hydrochloride (GMP) is Dap-NE hydrochloride (HY-78932A) produced by using GMP guidelines. Dap-NE hydrochloride is an intermediate used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15578G

McMMAF Maleimidocaproyl monomethylauristatin F	Biochemical Assay Reagents
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

HY-20336G

Mc-Val-Cit-PABC-PNP	Biochemical Assay Reagents
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-131833G

Fmoc-Gly-Gly-Phe-OH	Biochemical Assay Reagents
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133540G

Maleimide-DOTA Maleimido-mono-amide-DOTA	Biochemical Assay Reagents
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-131990G

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH	Biochemical Assay Reagents
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-131990). MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-128952G

Tesirine

SG3249

Biochemical Assay Reagents

Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

HY-135928

Biotin-C2-S-S-pyridine	Biochemical Assay Reagents
Biotin-C2-S-S-pyridine is a cleavable ADC linker. Biotin-C2-S-S-pyridine can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15579BG

MMAF sodium Monomethylauristatin F sodium	Biochemical Assay Reagents
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-78931G

Boc-Dap-NE	Biochemical Assay Reagents
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-163789

Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide	Biochemical Assay Reagents
Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

Cat. No.	Product Name	Target	Research Area

HY-P1449

Boc-Gly-Gly-Phe-Gly-OH	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-125586

β-Amanitin	DNA/RNA Synthesis ADC Payload	Cancer
β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .

HY-136432

Mc-Gly-Gly-Phe-Gly-PAB-OH Mc-GGFG-PAB-OH	ADC Linker	Cancer
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

HY-P4166

Ac-{Gly(N-me)}-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar	Peptides	Cancer
Ac-{Gly(N-me)}-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar is a decapeptide. Ac-{Gly(N-me)}-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar can be used to preparation of antibody-drug conjugate .

HY-42709

Z-Val-Ala-OH Carbobenzoxy-L-valyl-L-alanine	Amino Acid Derivatives	Cancer
Z-Val-Ala-OH is a dipeptide derivative of valine and alanine. Z-Val-Ala-OH undergoes cleavage by cathepsin B and other lysosomal proteases to enable payload release following lysosomal internalization. Z-Val-Ala-OH can be used for the research of antibody-drug conjugate (ADC) development[1] .

HY-P11295

Fmoc-GGFG-PAB-PNP	ADC Linker	Cancer
Fmoc-GGFG-PAB-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADC) .

HY-136432A

Mc-Gly-Gly-Phe-Gly-PAB-OH TFA Mc-GGFG-PAB-OH TFA	ADC Linker	Cancer
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) TFA is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

HY-P1449A

Boc-Gly-Gly-Phe-Gly-OH TFA	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-W1050525

Fmoc-Val-Ala-Gly	ADC Linker	Cancer
Fmoc-Val-Ala-Gly (compound 58a) is a cleavable ADC linker, can be conjugated to the antibody Trastuzumab (HY-P9907) to form an antibody-drug conjugate (ADC) .

HY-W729138

Fmoc-D-homoArg(Et)2-OH hydrochloride	ADC Linker	Others
Fmoc-D-homoArg(Et)2-OH (hydrochloride) is a Fmoc-protected derivative of D-Homoarginine (HArg) that renders peptides and proteins resistant to proteolysis by trypsin. Fmoc-D-homoArg(Et)2-OH (hydrochloride) can be used as a cleavable ADC linker to synthesize antibody-drug conjugates (ADCs) .

HY-P11804

DTyr-Gly-DTyr-Gly	ADC Linker	Cancer
DTyr-Gly-DTyr-Gly is a cleavable linker used in the synthesis of *antibody-drug conjugates* (ADCs) .

HY-P11805

Gly-Gly-DTyr-Gly-Gly	ADC Linker	Cancer
Gly-Gly-DTyr-Gly-Gly is a cleavable linker used in the synthesis of *antibody-drug conjugates* (ADCs) .

HY-P11807

DArg-DLys-DTyr-DTyr-Gly-DTrp	ADC Linker	Cancer
DArg-DLys-DTyr-DTyr-Gly-DTrp is a cleavable linker used in the synthesis of *antibody-drug conjugates* (ADCs) .

HY-P11806

DLeu-DTyr-Gly-DTrp-Gly-DTyr-DTrp	ADC Linker	Cancer
DLeu-DTyr-Gly-DTrp-Gly-DTyr-DTrp is a cleavable linker used in the synthesis of *antibody-drug conjugates* (ADCs) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99045

Sacituzumab 4 Publications Verification HRS7; hRS7	ADC Antibody TROP2	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-P99016

Enfortumab 1 Publications Verification	ADC Antibody Nectin-4	Cancer
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .

HY-P99843

Datopotamab 1 Publications Verification	TROP2 ADC Antibody	Cancer
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-P99016B

Enfortumab vedotin-ejfv (solution) 1 Publications Verification	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-P99349

Loncastuximab tesirine Loncastuximab tesirine-lpyl; ADCT-402	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). The antibody portion is Loncastuximab (HY-P99711), and the drug-linker conjugate for ADC is Tesirine (HY-128952). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a; I-DXd	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting *Antibody-drug conjugate* (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-P99151

Brentuximab 1 Publications Verification CAC-10	ADC Antibody TNF Receptor	Cancer
Brentuximab (CAC-10) is a chimeric antibody targeting CD30. Brentuximab is conjugated with Monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107A). Brentuximab can be used for the research of cancer, such as lymphoma .

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .

HY-P99043

Rovalpituzumab 1 Publications Verification SC-0001	Notch	Cancer
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .

HY-132253

Polatuzumab vedotin 1 Publications Verification	Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein	Cancer
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-P990673

Vandortuzumab DSTP-3086S Antibody; RG-7450 Antibody	ADC Antibody Transmembrane Glycoprotein Mitosis	Cancer
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99854

Disitamab 1 Publications Verification RC48-0	EGFR ADC Antibody	Cancer
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .

HY-P99971

Gemtuzumab	ADC Antibody Transmembrane Glycoprotein	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P99101

Vobramitamab AEX-4089; MGC026 Antibody	ADC Antibody	Cancer
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-P99956

Zilovertamab vedotin VLS-101; MK-2140	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer .

HY-P991041

Turmetabart Anti-SEZ6 Antibody (SC17); ABBV-011 Antibody; ABBV-706 Antibody	ADC Antibody	Cancer
Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99045A

Sacituzumab (powder)	ADC Antibody TROP2	Cancer
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent *antibody-drug conjugate* (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-P990047

Maridebart AMG133 Antibody	ADC Antibody GLP Receptor	Metabolic Disease
Maridebart (AMG133 antibody) is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody. Maridebart is the antibody portion of Maridebart cafraglutide (HY-164535) and can be used for the synthesis of antibody-drug conjugates (ADC). Maridebart can be used for the reserrch of obesity and type 2 diabetes .

HY-P99967

Cantuzumab	ADC Antibody	Cancer
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .

HY-141607

Indatuximab ravtansine BT-062; nBT062-DM4	Antibody-Drug Conjugates (ADCs) Bacterial	Cancer
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .

HY-P99271

Tisotumab Anti-Human F3 Recombinant Antibody	ADC Antibody	Cancer
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .

HY-P99285

Denintuzumab 1 Publications Verification hBU 12	ADC Antibody CD19	Cancer
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .

HY-P99682

Ladiratuzumab hLIV22	ADC Antibody	Cancer
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .

HY-P99453

Azintuxizumab	ADC Antibody	Cancer
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .

HY-P99007

Aprutumab BAY 1179470	FGFR	Cancer
Aprutumab (BAY 1179470) is a fully human fibroblast growth factor receptor 2 (FGFR2)-specific monoclonal antibody . Aprutumab induces FGFR2 endocytosis and degradation in cancer cells expressing FGFR2. Aprutumab serves as the targeted monoclonal antibody component of the antibody-drug conjugate BAY 1187982 (HY-141600) and mediates the endocytosis of the antibody-drug conjugate into FGFR2-positive cells. Aprutumab can be used for the research of FGFR2-positive solid tumors, including studies on gastric cancer and triple-negative breast cancer .

HY-P99740

Mirzotamab	CD276/B7-H3 ADC Antibody	Cancer
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P99788

Praluzatamab CX-191; CX-2009 Antibody	ADC Antibody ALCAM/CD166	Cancer
Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers .

HY-P99230

Pinatuzumab	Integrin CD22	Cancer
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990059

Puxitatug INT-016; AZD8205 Antibody	ADC Antibody CD276/B7-H3	Cancer
Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer .

HY-P99970

Lifastuzumab	ADC Antibody Sodium Phosphate Cotransporter	Cancer
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99718

Lupartumab BAY 1112623	ADC Antibody	Cancer
Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980 .

HY-145627

Ozuriftamab vedotin BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .

HY-P99656

Iladatuzumab MCDS0593A	ADC Antibody	Cancer
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .

HY-P99238

Rolinsatamab	ADC Antibody	Inflammation/Immunology Cancer
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an *antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug* attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C) .

HY-P99854A

Disitamab (powder) 1 Publications Verification RC48-0 (powder)	EGFR ADC Antibody	Cancer
Disitamab (RC48-0) (powder) is a humanized monoclonal antibody targeting HER2. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .

HY-P99334

Vorsetuzumab mafodotin Anti-Human CD70 Recombinant Antibody; SGN-75	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .

HY-P99685

Laprituximab emtansine IMGN-289; J2898A-SMCC-DM1	EGFR Antibody-Drug Conjugates (ADCs)	Cancer
Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR antibody-drug conjugate (ADC) consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research .

HY-P991742

LY4101174 Antibody 15A7.5; ETx-22 Antibody	ADC Antibody	Cancer
LY4101174 Antibody is an ADC antibody. LY4101174 is an antibody-drug conjugate (ADC) that targets the nectin-4 protein present on the surface of certain cancer cells. It can directly deliver a potent chemotherapy agent (Exatecan (HY-13631)) to the tumor site and is used for the study of advanced cancers, such as urothelial carcinoma, triple-negative breast cancer, and non-small cell lung cancer .

HY-P99264A

Inotuzumab (powder) Humanized Anti-CD22 Recombinant Antibody (powder)	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma . x

HY-P99662

Indusatumab vedotin MLN0264; TAK-264	Antibody-Drug Conjugates (ADCs) Guanylate Cyclase Apoptosis	Cancer
Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis .

HY-P99712

Lonigutamab hz208F2-4	IGF-1R Apoptosis ADC Antibody	Cancer
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye diseases .

HY-P990947

Tilatamig AZD9592 Antibody	ADC Antibody EGFR	Cancer
Tilatamig (AZD9592 Antibody) is a human antibody of the Ig (G1-κ_G1-λ2) subtype that targets EGFR/MET. Tilatamig conjugates with the Top1 inhibitor AZ14170133 (HY-145399) to form the antibody-drug conjugate (ADC) Tilatamig samrotecan (HY-171124) (AZD9592). Tilatamig accurately targets NSCLC models including EGFR-mutant, EGFR-wildtype, and EGFR tyrosine kinase inhibitor-treated ones, and its activity correlates with high expression of EGFR, c-MET and SLFN11. Tilatamig is available for in vivo anti-tumor studies in patient-derived xenograft models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) .

HY-P99921

Enapotamab vedotin HuMax-AXL-ADC	Antibody-Drug Conjugates (ADCs) TAM Receptor	Cancer
Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC). Enapotamab vedotin also exhibits resistant to EGFR inhibitor such as Osimertinib (HY-15772) .

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .

HY-P9994

Pertuzumab zuvotolimod SBT6050	Antibody-Drug Conjugates (ADCs) EGFR Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .

HY-P991668

PF-06688992 Antibody	ADC Antibody	Cancer
PF-06688992 Antibody is an antibody targeting GD3. PF-06688992 Antibody can be used for the synthesis of the antibody-drug conjugate PF-06688992 (HY-P991668) .

HY-P991505

Anti-HER3 Antibody (Ab562) AMT-562 Antibody	ADC Antibody EGFR	Cancer
Anti-HER3 Antibody (Ab562) is an anti-HER3 monoclonal antibody. Anti-HER3 Antibody (Ab562) can be used to synthesize the antibody-drug conjugate (ADC) AMT-562 (HY-171747) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-117371

Hemiasterlin (-)-Hemiasterlin; Milnamide B	Alkaloids Animals Classification of Application Fields Marine natural products Sponge Disease Research Fields Indole Alkaloids Cancer	ADC Payload
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effects. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-W007324

Maleimide	Alkaloids Microorganisms Pyrrole Alkaloids Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	ADC Linker Biochemical Assay Reagents
Maleimide can be used for production of antibody-drug conjugate (ADC) which is used in cancer research. Maleimide also be leveraged for the preparation of fluorogenic probe, which is mainly used for the specific detection of thiol analytes .

HY-W034595

Eicosanedioic acid	Microorganisms Source Classification	ADC Linker PROTAC Linkers
Eicosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Eicosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis

HY-W034918

Docosanedioic acid	other families Classification of Application Fields Ketones, Aldehydes, Acids Plants Disease Research Fields Source Classification Cancer	ADC Linker PROTAC Linkers
Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.

HY-W034918R

Docosanedioic acid (Standard)	Structural Classification other families Ketones, Aldehydes, Acids Plants Source Classification	ADC Linker Reference Standards PROTAC Linkers
Docosanedioic acid (Standard) is the analytical standard of Docosanedioic acid (HY-W034918). This product is intended for research and analytical applications. Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.

HY-W007324R

Maleimide (Standard)	Alkaloids Microorganisms Pyrrole Alkaloids Other Alkaloids Endogenous metabolite Source Classification	Reference Standards ADC Linker Biochemical Assay Reagents
Maleimide (Standard) is the analytical standard of Maleimide (HY-W007324). This product is intended for research and analytical applications. Maleimide can be used for production of antibody-drug conjugate (ADC) which is used in cancer research. Maleimide also be leveraged for the preparation of fluorogenic probe, which is mainly used for the specific detection of thiol analytes .

Cat. No.	Product Name	Chemical Structure

HY-15582S

Auristatin E-d8

Auristatin E-d₈ is the deuterium labeled Auristatin E (HY-15582). Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .

HY-161022S1

FL118-C3-O-C-amide-C-NH2-d5 formate
FL118-C3-O-C-amide-C-NH2-d5 formate is a deuterium labeled FL118-C3-O-C-amide-C-NH2 formate. FL118-C3-O-C-amide-C-NH2 formate is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-176415S

Cys-MC-GGFG-Dxd-d5
Cys-MC-GGFG-Dxd-d₅ is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd can be used in cancer research .

HY-I1129

Fmoc-3VVD-OH-d8
Fmoc-3VVD-OH-d₈ is a deuterium labeled Fmoc-3VVD-OH (HY-78921). Fmoc-3VVD-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15583S

Auristatin F-d8
Auristatin F-d₈ is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .

HY-145397S

(4-NH2)-Exatecan-d5
(4-NH2)-Exatecan-d5 is a deuterated labeled (4-NH2)-Exatecan . (4-NH2)-Exatecan (compound A), a topoisomerase inhibitor, is a derivative of Exatecan. (4-NH2)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-145399S

AZ14170133-d5
AZ14170133-d₅ (SG 3932-d₅) is the deuterium labeled AZ14170133 (HY-145399). AZ14170133 (SG 3932) is a Drug-Linker Conjugates for ADC, which comprises a topoisomerase inhibitor and a linker for ligand unit connecting. AZ14170133 can be used to synthesis antibody-drug conjugate (ADC) .

HY-114816S

N-butyryl-L-Homoserine lactone-d5

N-butyryl-L-Homoserine lactone-d₅ is the deuterium labeled N-Butanoyl-L-homoserine lactone. N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm . N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa .

HY-19792S2

Mertansine-d3
Mertansine-d₃ (DM1-d₃) is the deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-19792S

Mertansine-13C,d3

Mertansine- ¹³C,d₃ (DM1- ¹³C,d₃) is the ¹³C- and deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-176415S1

Cys-MC-GGFG-Dxd-d5 TFA
Cys-MC-GGFG-Dxd-d5 TFA (Cys-MC-GGFG-Dxd-d₅ TFA) is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd-d5 TFA is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd-d5 TFA is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd-d5 TFA can be used in cancer research .

Targets Recommended: Antibody-Drug Conjugates (ADCs) ADC Linker

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-78921AG

Fmoc-3VVD-OH	ADC Linker	Cancer
Fmoc-3VVD-OH (GMP) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78932G

Dap-NE hydrochloride	ADC Linker	Cancer
Dap-NE hydrochloride (GMP) is Dap-NE hydrochloride (HY-78932A) produced by using GMP guidelines. Dap-NE hydrochloride is an intermediate used in the synthesis of antibody-drug conjugates (ADCs) .

HY-131833G

Fmoc-Gly-Gly-Phe-OH	ADC Linker	Cancer
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-133540G

Maleimide-DOTA Maleimido-mono-amide-DOTA	ADC Linker	Inflammation/Immunology Cancer
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15579BG

MMAF sodium Monomethylauristatin F sodium	Microtubule/Tubulin ADC Payload	Cancer
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-78931G

Boc-Dap-NE	ADC Linker	Cancer
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-W000423G

DBCO-amine	Biochemical Assay Reagents	Cancer
DBCO-amine (GMP) is a GMP grade DBCO-amine (HY-W000423). DBCO-amine is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups. DBCO-amine is used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15578G

McMMAF Maleimidocaproyl monomethylauristatin F	Drug-Linker Conjugates for ADC	Cancer
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

HY-20336G

Mc-Val-Cit-PABC-PNP	ADC Linker	Cancer
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-15579G

MMAF Monomethylauristatin F	Microtubule/Tubulin ADC Payload	Cancer
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-131990G

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH	ADC Linker	Cancer
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-131990). MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-128952G

Tesirine SG3249	Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker	Cancer
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Antibody-Drug+Conjugates

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Natural
Products